PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

Dr. Villy Valcheva, CEO of GH Research, expressed optimism about the trial's results, stating, "Today, as we share our unprecedented positive Phase 2b data, we celebrate a significant milestone in our ...

Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...